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Abstract
Background: Nitration of proteins on tyrosine residues, which can occur due to polluted air under ‘‘summer smog’’
conditions, has been shown to increase the allergic potential of allergens. Since nitration of tyrosine residues is also
observed during inflammatory responses, this modification could directly influence protein immunogenicity and might
therefore contribute to food allergy induction. In the current study we have analyzed the impact of protein nitration on
sensitization via the oral route.
Methodology/Principal Findings: BALB/c mice were immunized intragastrically by feeding untreated ovalbumin (OVA),
sham-nitrated ovalbumin (snOVA) or nitrated ovalbumin (nOVA) with or without concomitant acid-suppression. To analyze
the impact of the sensitization route, the allergens were also injected intraperitoneally. Animals being fed OVA or snOVA
under acid-suppressive medication developed significantly elevated levels of IgE, and increased titers of specific IgG1 and
IgG2a antibodies. Interestingly, oral immunizations of nOVA under anti-acid treatment did not result in IgG and IgE
formation. In contrast, intraperitoneal immunization induced high levels of OVA specific IgE, which were significantly
increased in the group that received nOVA by injection. Furthermore, nOVA triggered significantly enhanced mediator
release from RBL cells passively sensitized with sera from allergic mice. Gastric digestion experiments demonstrated protein
nitration to interfere with protein stability as nOVA was easily degraded, whereas OVA and snOVA remained stable up to
120 min. Additionally, HPLC-chip-MS/MS analysis showed that one tyrosine residue (Y107) being very efficiently nitrated is
part of an ovalbumin epitope recognized exclusively after oral sensitization.
Conclusions/Significance: These data indicated that despite the enhanced triggering capacity in existing allergy, nitration
of OVA may be associated with a reduced de novo sensitizing capability via the oral route due to enhanced protein
digestibility and/or changes in antibody epitopes.
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Introduction
The prevalence of type I allergies is steadily increasing in
Western societies [1]. A reduced exposure to microbial pathogens
in childhood has been discussed to represent one of the major
causes, summarized in the so-called hygiene hypothesis [2].
However, additional risk factors including individual (e.g. nutrition
and medication) as well as environmental factors play an essential
role in allergy induction.
In the last decades, ambient pollutants, combustion generated
particles and polycyclic aromatic hydrocarbons associated with
them have been identified as health problems with substantial
impact on our immune responses [3–5]. The components of smog,
NO2 and O3, have been discussed to chemically alter airborne
proteins, resulting in e.g. protein nitration. This effect has been
demonstrated for Bet v1, the major birch pollen allergen, with was
detected in nitrated form in dust samples from various urban
environments [6]. Nitration of protein tyrosine residues, resulting
in 3-nitrotyrosine formation, changes the conformation of
proteins, being of special importance for B-cell epitopes and
may, thus, alter not only protein function but also IgE recognition
substantially [7]. Slight modifications of amino acids within
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14210proteins by nitration can increase or diminish the potential of
epitope binding to immunoglobulins. Even though the dramatic
effect of some point mutations on IgE binding has been elucidated
using Bet v1 as a model allergen [8,9], nitration has been discussed
to especially alter IgG epitopes [10]. However, a recent study has
revealed that the allergenic potential of Bet v1 for inducing IgE-
dependent type 1 allergy is also increased by protein nitration [11].
Additionally, nitration of Bet v1 was demonstrated to be associated
with an enhanced antigen processing and presentation by
dendritic cells leading to a stronger stimulation of Bet v1 specific
T cells (Karle AC et al. Unpublished data).
While tyrosine nitration due to environmental air pollutants was
noted only recently, protein nitration has previously been
described to occur within inflammatory conditions and as a result
of the ageing process in the human body [12]. Nitration of tyrosine
residues from self-antigens may promote the development of
autoimmune reactions by evasion of immunological self-tolerance
[13]. Additionally, protein nitration can occur in situations like
inflammatory bowel diseases or Helicobacter (H.) pylori infections
[14,15]. Under these circumstances, common proteins of the daily
diet might undergo modification by nitration with major impact
on immunogenicity and consequently also on food allergy
induction.
Already in the 1980ies, the association between gastrointestinal
inflammations and a higher incidence of food allergy has been
reported, with food allergic reactions being attributed to
hereditary and alimentary factors [16]. Later, an association
between H. pylori infection and food allergy was reported [17–19]
and high levels of total and food-specific IgE were measured in the
gastrointestinal mucosa of peptic ulcer patients [20,21]. On the
one hand the correlation of gastric ulcers and food allergy was
discussed as a result of enhanced mucosal permeability in H. pylori
infection [22]; on the other hand the current treatment of
dyspeptic disorders with acid-suppression medication was revealed
as a causative factor for IgE formation [23–25].
It is conceivable that protein nitration induced during
inflammatory responses in the stomach could directly influence
protein immunogenicity and thus contribute to food allergy
induction. In the present study we aimed to investigate the
influence of protein nitration on allergy induction via the oral
route using a previously established murine food allergy model
[23,26].
Results
Characteristics of nOVA proteins
Spectrophotometric analysis of nOVA samples revealed a
21% nitration grade of the 10 tyrosine residues. Addi-
tionally, we investigated the location of nitrated tyrosine residues
within the nOVA protein and evaluated the nitration degree of the
tyrosine residues by HPLC-chip-MS/MS analysis. Native OVA
consists of 386 amino acid residues including 10 tyrosine residues.
In the HPLC-chip-MS/MS analysis of nOVA we could identify
11 tryptic peptides and achieved an amino acid coverage of 33%.
Three tyrosine residues could be located in native (Y112,Y 118 and
Y282) and nitrated (Y107,Y 112 and Y282) form (Table 1).
Oral immunizations result in elevated titers of IgG1 and
IgG2a when OVA or snOVA are fed under acid-suppre-
ssion. After 6 immunization cycles with OVA, snOVA or
nOVA (Figure 1, Table 2) enzyme-linked immuno sorbent assay
(ELISA) screening of OVA-specific antibodies in murine serum
samples demonstrated an increase of OVA-specific IgG1 only in
the animals being fed OVA and snOVA under concomitant
gastric acid suppression. All other animals immunized ig.,
including those being fed nOVA with or without anti-acid
medication, did not develop detectable levels of specific IgG1
antibodies during the time course of repeated immunization
(Figure 2A). Accordingly, IgG2a was only elevated in the groups
being orally immunized either with OVA or snOVA after six
immunization cycles (Figure 2B). Analyzing the impact of the
route of sensitization, the 3 groups immunized intraperitoneally
(ip.) with OVA, snOVA or nOVA revealed elevated levels of
OVA-specific IgG1 and IgG2a (Figure 2A, B).
Table 1. HPLC-chip-MS/MS-analysis.
Position Sequence
RT
(min) z
m/z
(Da)
mt
(Da)
native
tyrosine
nitrated
tyrosine NDY
a
105–112 (R)LYAEER(Y) 1.13 2 413.19 780.39 Y107 1
111–124 (R)YPILPEYLQCVK(E) 14.10 2 761.90 1522.80 Y112;Y 118
111–124 (R)YPILPEYLQCVK(E) 15.19 2 784.80 1522.80 Y118 Y112 0.1160.08
127–144 (R)GGLEPINFQTAADQAR(E) 11.96 3 844.42 1687.84
143–160 (R)ELINSWVESQTNGIIR(N) 14.48 2 929.99 1858.97
187–201 (K)AFKDEDTQAMPFR(V) 1.45 3 519.24 1555.72
190–201 (K)DEDTQAMPFR(V) 1.53 2 605.26 1209.52
264–278 (K)LTEWTSSNVMEER(K) 10.02 2 791.36 1581.72
280–286 (K)VYLPR(M) 1.13 2 324.20 647.39 Y282
280–286 (K)VYLPR(M) 1.46 2 346.69 647.39 Y282 0.1460.19
323–341 (K)ISQAVHAAHAEINEAGR(E) 1.09 2 887.45 1773.90
340–361 (R)EVVGSAEAGVDAASVSEEFR(A) 11.84 2 1004.98 2008.95
370–383 (K)HIATNAVLFFGR(C) 13.39 3 449.25 1345.74
370–383 (K)HIATNAVLFFGR(C) 13.39 2 673.37 1345.74
aNDY= Initrated/(Initrated+Inative); I (Intensity).
Identified tryptic peptides of nOVA: amino acid sequence, retention time (RT), measured mass-to-charge ratio (m/z), charge stage (z), theoretical molecular mass (mt)
tyrosine residue and calculated nitration degrees of individual tyrosine residues (NDY).
doi:10.1371/journal.pone.0014210.t001
OVA Nitration and Food Allergy
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animals immunized orally with OVA or snOVA under acid-
suppression. To obtain information about the allergic status of
the animals, a serological screening for OVA-specific IgE
antibodies was performed. ELISA measurements confirmed the
pattern observed for IgG1 and IgG2a. Only animals immunized
Figure 1. Flow diagram of the applied immunization protocol. Animals divided in 10 groups (n=6) were repeatedly immunized with OVA,
snOVA or nOVA either with or without concomitant gastric acid-suppression. Furthermore, 3 groups were injected the respective allergens ip. A
control group remained naı ¨ve. Blood for measurement of antibody titers was collected on days 0, 14, 28, 42, 56, 91 and 105.
doi:10.1371/journal.pone.0014210.g001
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suppressed and in the groups immunized ip. with OVA, snOVA
and nOVA developed elevated titers of specific IgE antibodies
during the immunization cycles. Again, only background levels
were measured in the groups being immunized orally with nOVA
(Figure 3A). Interestingly, ip. injections of nOVA resulted in
significantly elevated IgE titers compared to the animals being
injected OVA or snOVA.
To confirm the functional relevance of the detected IgE
antibodies, RBL assays using OVA as the triggering antigen were
performed. In accordance with the ELISA results, mediator
release could be detected only in the groups immunized with OVA
or snOVA ig. under acid-suppression as well as in the groups being
immunized ip. with OVA, snOVA or nOVA (Figure 3B). Highest
levels of released mediators were measured in animals of the group
being immunized ip. with the triggering allergen OVA.
Increased cytokine levels are measured in gastric tissue
samples of acid-suppressed animals after oral immuni-
zation. To further analyze the immune events induced by the
various treatments, cytokine levels at the site of allergy induction
were evaluated in semi-quantitative RT-PCR experiments. We
used gastric tissue samples from mice being immunized with anti-
acid treatment via the oral route and compared the determined
levels to those measured in samples from animals receiving the
respective allergen without acid suppression. In line with the
serological evaluations, increased levels of the Th2 cytokines IL5
and IL13, the eosinophil chemoattractants CCL11 and CCL24, as
well as the inflammatory marker TNF-a were observed in the
groups being fed OVA or snOVA under concomitant acid-
suppression. In the animals which were orally immunized with
nOVA under acid-suppression only CCL24 levels were elevated,
whereas for all other measured cytokines and inflammatory
markers comparable levels were detected as in tissue samples
from animals being fed nOVA alone (Table 3).
nOVA induces significantly enhanced mediator release in
RBL cells. RBL cells sensitized with sera from the different
immunization groups were incubated with OVA (Figure 4, blue
boxes), nOVA (Figure 4, green boxes) or nitrated Bet v1 (Figure 4,
beige boxes). Interestingly, a significant increase of released
mediators was observed in the groups positive for OVA-specific
IgE (the acid-suppressed animals receiving OVA and snOVA ig.
Figure 2. Elevated titers of OVA-specific IgG1 and IgG2a antibodies are observed after oral immunizations with OVA and snOVA
under gastric acid suppression. (A) Increased levels of OVA-specific IgG1 antibodies are detected in the gastric acid suppressed animals receiving
OVA or snOVA ig. as well as in the groups immunized ip. with OVA, snOVA and nOVA. Animals of groups fed with OVA, snOVA or nOVA alone or
nOVA under gastric acid suppression and the naı ¨ve animals revealed only marginal or undetectable IgG1 titers. (B) Specific IgG2a antibodies are also
detected only in animals immunized with OVA or snOVA ig. under concomitant gastric acid suppression as well as in the ip. injected groups. In the
other groups the levels remained at the baseline. The boxes represent the inner quartiles value range of the six immune sera with the median
indicated. Sera with signals more than 1.5-fold interquartile range deviation from the end of the box were defined as outliers and marked as circles.
Sera with titers lying more than 3-fold interquartile range away were defined as extremes and marked with asterisks. Brackets indicate the groups
with statistical significant differences in antibody titers (**P,0.01).
doi:10.1371/journal.pone.0014210.g002
Table 2. Immuization protocol.
Group label Immunized with
OVA ig. + PPI 116 mg PPI, 200 mg OVA +2 mg sucralfate ig.
OVA ig. 200((g OVA ig.
OVA ip. 2((g OVA +2% Al(OH)3 ip.
snOVA ig. + PPI 116 mg PPI, 200 mg snOVA +2 mg sucralfate ig.
snOVA ig. 200 mg snOVA ig.
snOVA ip. 2 mg snOVA +2% Al(OH)3 ip.
nOVA ig. + PPI 116 mg PPI, 200 mg nOVA +2 mg sucralfate ig.
nOVA ig. 200((g nOVA ig.
nOVA ip. 2((g nOVA +2% Al(OH)3 ip.
Naive —
doi:10.1371/journal.pone.0014210.t002
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when nOVA was used as the triggering antigen (Figure 4, green
boxes). The increase of released mediators was especially
pronounced in the RBL cells immunized with sera after ip.
immunizations with nOVA, where the effect even exceeded the
release induced by control incubations with the detergent Triton
X-100.
In the cells sensitized with sera from the ip. immunized groups
an additional elevated release upon challenge with nitrated Bet v1
was observed (Figure 4, beige boxes).
Digestion experiments demonstrate the rapid degrada-
tion of nOVA under physiological gastric condi-
tions. Simulated gastric fluid (SGF) experiments with the
immunization antigens OVA, snOVA and nOVA revealed
digestion of nOVA proteins (Figure 5C) within 5 min under
physiologically low pH levels (pH1). OVA (Figure 5A) and snOVA
(Figure 5B) remained stable up to 120 min when being incubated
with gastric enzymes at low pH. When the pH of SGF was
adjusted to pH 3 and 5 simulating situations of elevated gastric pH
conditions, all 3 protein preparations were not degraded during
the entire incubation time of 120 min.
Discussion
In the present study we investigated the allergenic potential of
chemically nOVA in a murine model of food allergy. Interestingly,
we observed a reduced sensitization capacity of nOVA upon oral
antigen administration. However, systemic administration of
nOVA induced high titers of biologically functional IgE
antibodies. Additionally, the nitrated proteins induced a signifi-
cantly higher mediator release of effector cells being sensitized
with sera of allergic animals. In contrast to OVA, gastric digestion
experiments revealed nOVA to be degraded within a few minutes
under physiologically low pH conditions.
Our study underlines the importance of considering differences
in administration routes in experimental models of food allergy.
Figure 3. Functional IgE antibodies are detected in the acid-suppressed animals fed with OVA and snOVA and after systemic
administration of OVA. (A) ELISA measurements confirmed the presence of OVA-specific IgE antibodies in the groups fed OVA and snOVA under
anti-acid medication (OVA ig.+PPI, snOVA ig.+PPI) and in the ip. immunized groups (OVA ip., snOVA ip. and nOVA ip.). After systemic administration,
antibody titers were significantly elevated when using nOVA, compared to OVA and snOVA (**P,0.01). Screening of murine sera from groups
immunized with OVA ig., snOVA ig., nOVA ig. under concomitant anti-acid medication, nOVA ig. and from the naı ¨ve animals demonstrated only basal
IgE levels. (B) The biological functionality of the detected IgE antibodies could be confirmed in an RBL assay using sera collected after the repeated
immunization cycles. Again elevated levels of released mediators could be triggered upon OVA stimulations with sera of the acid suppressed animals
receiving OVA or snOVA ig., as well as with sera from the ip. injected groups. The boxes represent the inner quartiles value range with the median
indicated as black line. Outliers and extremes are marked with circles and asterisks. Brackets specify the groups with statistically significant differences
in released mediator levels (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0014210.g003
Table 3. RT-PCR cytokine evaluation of gastric tissue samples
from orally immunized animals.
IL 5 IL13 CCL11 CCL24 TNFa
OVA ig.+PPI
Mean 2.4998 2.0753 1.1825 22.4612 2.512
Lower 95% CI 0.0 0.0 0.0 9.6095 0.7776
Upper 95% CI 5.974 4.4966 2.8039 35.3130 5.8017
snOVA ig.+PPI
Mean 2.6246 9.9665 1.5226 0.8021 1.8883
Lower 95% CI 1.7774 0.0 0.9745 0.0 1.3081
Upper 95% CI 7.0266 34.4637 2.0706 1.9229 2.4685
nOVA ig.+PPI
Mean 1.2252 0.8637 0.9019 15.7047 0.6863
Lower 95% CI 0.0 0.0 0.0 0.0 0.5820
Upper 95% CI 2.6872 1.8387 1.9966 59.3320 0.7906
Fold increase of levels measured in animals immunized ig. with OVA, snOva and
nOVA under concomitant acid suppression to animals immunized with the
respective allergen ig. is presented.
doi:10.1371/journal.pone.0014210.t003
OVA Nitration and Food Allergy
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models are crucial tools to analyze mechanisms of food allergic
reactions and the allergenic potential of dietary proteins [28]. Our
group has previously reported that feedings under impaired gastric
digestion conditions by elevating the gastric pH results in
development of food allergy [23,24]. These findings helped to
establish a mouse model of food allergy [26], reflecting the
situation in allergic patients [24,25]. This murine immunization
protocol was applied in the current study to investigate the impact
of food protein nitration on oral sensitization.
Chemical protein modification has been discussed to be of
interest with respect to allergic reactions. Special attention has
been given to the reduction of the allergic potential by chemical
alterations [29–31] and to possible implications on the develop-
ment of novel treatment strategies [32]. It has also been
recognized that environmental pollutants can modify pollen
allergens chemically [6] with impact on antibody recognition
[7]. Nitrated Bet v1 as well as nOVA have increased allergenicity
[11]. In line with these findings, we found nOVA to have
enhanced triggering capacity on effector cells in our experiments.
When testing with sera of allergic animals, the allergenicity of
OVA proteins was enhanced if tyrosine residues were nitrated.
Murine IgE antibodies specifically interacted with nOVA leading
to an elevation of mediator release if immunizations were
performed via the oral route. However, when animals received
the OVA preparations systemically via ip. injections, an additional
cross-recognition of an unrelated nitrated allergen (Bet v1) was
observed even if the animals were sensitized with OVA or snOVA
[11].
The results of the SGF experiments indicate that nitration of
tyrosine residues interferes with the protein stability in the
presence of gastric digestive enzymes. The acidic gastric milieu
has been discussed to play an important role in nitration as nitrous
acid was found to be formed exclusively at low pH, having then
the ability to nitrate tyrosine residues of ingested proteins [33].
Nitrated proteins were demonstrated to be cleaved by the
pancreatic enzyme chymotrypsin at a significantly slower rate
than untreated peptides [34]. After 4 hours of chymotrypsin
digestion, 40% of nitrated peptides remained stable compared to
10% of untreated peptides [7]. To our knowledge this is the first
report describing that nitration enhances the digestibility of food
proteins by gastric enzymes. Pepsin is known to cleave proteins
Figure 4. Elevated levels of released mediators are detected when triggering sensitized RBL cells with nOVA. RBL cells sensitized with
the 6
th immune serum from the immunized or naı ¨ve animals were challenged with OVA (blue boxes), nOVA (green boxes) or nitrated Bet v1 (beige
boxes). An enhanced mediator release was observed upon triggering with nOVA in RBL cells sensitized with sera of groups fed with OVA and snOVA
under anti-acid medication. This elevated mediator release was also observed with sera from the positive control groups (OVA, snOVA and nOVA ip.),
which additionally reacted with nitrated Bet v1. No mediator release with any of the allergens was observed in RBL cells sensitized with sera of groups
immunized with OVA ig., snOVA ig., nOVA ig. under concomitant anti-acid medication, nOVA ig. and of the naı ¨ve animals, where no IgE was detected.
The boxes represent the inner quartiles value range with the median indicated as black line. Outliers and extremes are marked with circles and
asterisks. Brackets indicate the groups with statistical significant differences in released mediator levels (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0014210.g004
OVA Nitration and Food Allergy
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[35,36]. Due to conformational changes upon nitration of tyrosine
residues, amino acids interacting with pepsin might become
accessible leading to an enhanced susceptibility to gastric, digestive
proteases and a reduced immunogenicity if administered via the
oral route. However, we have repeatedly demonstrated that our
oral immunization protocol of protein feeding under concomitant
acid suppression results in allergic sensitization indicated by
specific IgE antibodies, leading to the development of food allergy
even if food proteins were easily degraded by gastric enzymes
[23,24,26,37]. Thus, it might be of special interest that the most
efficiently nitrated tyrosine residue within the nOVA protein (Y107)
is part of human as well as murine IgE epitopes of ovalbumin
[38,39] and is also found in a human ovalbumin T cell epitope
[40]. Using different routes of allergen application in BALB/c
mice, ovalbumin epitopes were analyzed by induced antibodies
revealing the tyrosine residue Y107 to be part of an ovalbumin
epitope recognized exclusively after oral sensitization [39]. This
Figure 5. Digestion experiments reveal nitration of OVA to interfere with its resistance against gastric digestive enzymes. SGF
experiments with (A) OVA, (B) snOVA and (C) nOVA reveal rapid degradation within 5 minutes only when incubating nitrated OVA with gastric
enzymes at physiological gastric conditions (pH 1). At elevated pH levels (pH 3 and 5) all protein samples remained stable for up to 120 min.
doi:10.1371/journal.pone.0014210.g005
OVA Nitration and Food Allergy
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no IgG1 or IgG2a formation was observed after oral immuniza-
tions with nOVA.
Our data demonstrate that nitration of OVA, as it might occur
endogenously e.g. during inflammatory processes, results in
reduced de novo sensitization capacity of this common egg white
allergen via the oral route underlining the importance of
gastrointestinal digestion in food allergy. Nevertheless, in situations
where patients are sensitized and effector cells of allergy are
already armed with allergen specific IgE, contact with the nitrated
allergen e.g. by inhalation might result in an increased release of
preformed mediators as indicated by elevated triggering capacity.
Materials and Methods
Antigen preparation
Lyophilized OVA (Sigma, Vienna, Austria, 98% purity) was
used for all experiments. Proteins were nitrated or sham-nitrated
as previously described [11]. For nitration, allergens were
dissolved in PBS and nitrated using tetranitromethane dissolved
in methanol (Merck, Darmstadt, Germany). Nitrated proteins
were purified by size exclusion chromatography (PD-10 columns,
Pharmacia, Uppsala Sweden) and the amount of 3-nitrotyrosine
residues was determined by spectrophotometry at 440 nm, after
dilution in 0.05 M NaOH. The spectrophotometer was calibrated
with free 3-nitrotyrosine. Sham-nitration of allergens was per-
formed using the same protocol, however without addition of
tetranitromethane. Nitration of OVA was additionally confirmed
by ELISA. Microtiter plates (Maxisorp, NUNC, Roskild, Den-
mark) were coated with 1 mg untreated, sham-nitrated or nitrated
OVA per well. After blocking with TBST (Tris buffered saline
with Tween-20) with 1% dried milk powder (DMP), monoclonal
mouse nitrotyrosine-specific antibody (clone HM11; Invitrogen,
Camarillo, CA) diluted 1:1000 in TBST/0.1% DMP were
incubated overnight at 4uC. Bound antibodies were detected
using peroxidase labeled goat anti-mouse IgG (Abcam, Cam-
bridge, UK, diluted 1:5000). For detection, TMB (tetramethyl-
benzidine, BD Bioscience, Vienna, Austria) was added for 10
minutes and the reaction was stopped with 1.8 M H2SO4. The
color reaction was measured at 450–630 nm.
HPLC-chip-MS/MS analysis of nOVA
After nitration nOVA samples were subjected to the HPLC-
chip-MS/MS analysis. The tryptic digested and desalted protein
samples were analyzed with a HPLC-chip MS/MS system
consisting of a nano pump (G2226A, Agilent) with 4-channel
micro-vacuum degasser (G1379B, Agilent), a microfluidic chip
cube (G4240-64000, Agilent) interfaced to a Q-TOF mass
spectrometer (6520, Agilent; nominal mass resolution 20000 at a
scan rate of 5 s
21), a capillary pump (G1376A, Agilent) with
degasser (G1379B, Agilent), and an autosampler with thermostat
(G1377A, Agilent). All modules were controlled by Mass Hunter
software (version B.02.00, Agilent). A microfluidic reversed phase
HPLC chip (Zorbax 300SB-C18, 5 mm particle size, 75 mm i.d.,
and 150 mm length) was used for peptide separation. For each
chromatographic run, the solvent gradient started with 97% water
with formic acid (HCOOH volume fraction 0.1%, Chromasolv,
Sigma, Seelze, Germany) and 3% acetonitrile at 600 nL min
21.
Then the acetonitrile (Chromasolv, Sigma, Seelze, Germany)
content was increased to 70% within 28min. Finally, the mobile
phase was reset to initial conditions within 0.1 min, and the chip
was equilibrated for 2 min before the next run. The ESI-Q-TOF
instrument was operated in the positive ionization mode (ESI+)
with an ionization voltage of 1750 V and a fragmentor voltage of
175 V at 300uC. Fragmentation of protonated molecule ions was
conducted in the auto MS/MS mode starting with a collision
energy voltage of 2.5 V that was increased by 3.7 V per 100 Da.
The selected m/z ranges were 300 to 2400 Da in the MS mode
and 59 to 3000 Da in the MS/MS mode. The instrument settings
were 4 s
21 for the MS scan rate and 3 s
21 for the MS/MS scan
rate. The data output was one full mass spectrum with three
fragmentation patterns per mass spectrum every 250 ms. The
three highest peaks of an MS spectrum were selected for
fragmentation. If the highest peaks were the same in two
consecutive MS spectra, they were excluded from further MS/
MS analysis (fragmentation) for the subsequent 0.08 min.
Reference correction of detected ions was enabled during the
whole analysis. Database searches were performed with the
Spectrum Mill software (version A.03.03.084, Agilent) against
the database Swiss-Prot (www.expasy.ch). Protein identification
and the search for post-translational modifications including
nitration were performed with the Spectrum Mill software [41].
Animals
Eight to ten weeks old female BALB/c mice were purchased
from the Institute of Laboratory Animal Science and Genetics,
Medical University of Vienna, Austria. All experiments were
approved by the ethics committee for animal studies of the
Medical University Vienna and by the Austrian Federal Ministry
of Science and Research (permission number GZ BMBWK-
66.009/0001-BrGT/2007). The experiments were performed in
accordance with the European Community rules of animal care.
Immunization protocol
For investigating the effect of protein nitration on food allergy
induction, our previously established murine food allergy model
[26] was used. In short, animals were divided into 10 groups (n=6
each, Table 1). Three groups were medicated intravenously with a
proton pump inhibitor (PPI; omeprazole) for 3 days (on days 1–3,
15–17, 29–31, 43–45, 76–78 and 92–94). Fifteen minutes after a
repeated i.v. injection of the PPI, mice were immunized orally with
the different OVA preparations (0.2 mg of OVA, snOVA or
nOVA per mouse) mixed with 2 mg sucralfate (UlcogantH, Merck)
on days 2–3, 16–17, 30–31, 44–45, 77–78 and 93–94. On the
same days three other groups were fed the respective allergen
(OVA, snOVA and nOVA) without acid suppression.
To compare different routes of exposure, six animals were
immunized ip. with 2 mg OVA adsorbed to 2% aluminum
hydroxide solution (1.3 mg Al(OH)3), another group of animals
received 2 mg snOVA adsorbed to 2% aluminum hydroxide
solution and a third group was injected 2((g nOVA in 1.3((g
Al(OH)3 on days 3, 17, 31, 45, 78 and 94. The negative control
group remained naı ¨ve. Blood samples were taken on days 0, 14,
28, 42, 56, 91 and 105 (Figure 1, Table 2).
Evaluation of OVA specific antibodies in ELISA and RBL-
assay experiments
Murine sera were screened for OVA specific antibody
subclasses (IgG1, IgG2a, IgE) in ELISA. Microtiter plates
(Maxisorp, NUNC) were coated with 1 mg OVA per well. After
blocking with TBST/1% DMP, mouse sera diluted 1:100 for IgG1
and IgG2a and 1:10 for IgE in TBST/0.1% DMP were incubated
overnight at 4uC. Bound antibodies were detected using rat anti-
mouse IgG1, IgG2a or IgE (BD Biosciences, Franklin Lakes, NJ;
1:500) followed by a peroxidase labeled goat anti-rat IgG
(Amersham, diluted 1:1000). For detection, TMB (BD Bioscience)
was added for 15 min and the reaction was stopped with 1.8 M
OVA Nitration and Food Allergy
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concentrations were calculated according to standard dilution
series after subtracting levels detected in pre-immune sera as
background values.
To evaluate biologically active OVA specific IgE, a rat-basophil
leukemia cell assay (RBL-assay) was performed [42]. RBL-2H3
cells, exclusively expressing the mouse high affinity IgE receptor
FceRI [43], were passively sensitized with murine sera diluted 1:10
and incubated at 37uC for 1 hour. After washing, 10 mg/mL
OVA, nitrated OVA or 3((g/mL nitrated Bet v1 were added to the
appropriate wells. The induced (-hexosaminidase release was
measured in a fluorometer using 4-Methylumbelliferyl (-D-
galactopyranoside (4-MUG, Sigma, Vienna, Austria) at 360–
465 nm. Calculations were made by correlating measured values
with (-hexosaminidase release of Triton X-100 (Sigma) stimulated
cells, which was set 100%.
RNA isolation, reverse transcription and real-time PCR
analysis
After sacrifice of the animals, gastric tissue was shock-frozen in
liquid nitrogen for further analysis. Total RNA was isolated from
gastric tissue samples for evaluation of target gene (TNFa, IL5,
IL13, CCL11, CCL24) expression by using the RNeasy RNA
isolation Kit (Qiagen, Vienna, Austria), following the manufac-
turer’s instruction. RNA concentration and purity was determined
using the Nanodrop-1000 (Peqlab, Erlangen, Germany). Two mg
of total RNA were transcribed into cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Vienna, Austria).
Expression analysis was performed by real-time PCR on a
StepOne Plus real-time PCR system (Applied Biosystems). The
analysis was carried out with a two step protocol starting with 20
seconds at 95uC, followed by 40 cycles of 1 second at 95uC and
subsequent 20 seconds at 60uC. In all experiments duplicates were
set up containing the POWER SYBR Green PCR Master Mix
(Applied Biosystems) reagent. Primers were designed using
‘‘Primer Express 2.6’’ software (Applied Biosystems) and span,
when possible, exon–intron boundaries to avoid signals from
contaminating genomic DNA. The forward (fwd) and reverse (rev)
primers consist of the following sequences: beta Actin fwd:
cgatggtgtcactgggctc, rev: ccaccgatccacacagagtactt; CCL11 fwd:
tccacagcttctattcct, rev: ctatggctttcagggtgcat; CCL24 fwd: ac-
cccagctttgaactctga, rev: aaggacgtgcagcaagatg; TNFa fwd:
ctccctctcatcagttctatgg, rev: ctccacttggtggtttgctac; IL13 fwd: tatt-
gaggagctgagcaacatcac, rev: tctgggtcctgtagatggca; IL5 fwd: tgttga-
caagcaatgagacgatga, rev: ggacagtttgattcttcagtatgtc.
Based on melting curve analysis no primer–dimers were
generated during the PCR amplification. For relative quantifica-
tion, the expression levels of target genes were analyzed using
‘‘StepOne software 2.0’’ (Applied Biosystems) and normalized to
the average of the house keeping gene beta-actin. The values are
represented as 2‘(-DDCT). For calculation of fold increase the
determined expression values in animals immunized with OVA,
snOVA or nOVA under gastric acid suppression were normalized
to the levels derived for the groups being fed with the respective
allergen alone.
Digestion experiments
SGF was prepared with a pharmaceutical enzyme tablet
(EnzynormH forte, Pharmaselect Handels GmbH, Vienna,
Austria) as previously described [44] with slight modifications:
One tablet was dissolved in 100 mL 0.9% sterile sodium chloride
at pH 1.0, pH 3.0 or pH 5.0. For digestion, 500 mL of SGF was
incubated with 500((g OVA, snOVA or nOVA. The digestion was
quenched with 0.1 N NaOH after 1, 5, 15, 30, 60 and 120 min.
The effect of incubation with SGF on protein integrity was
evaluated in SDS-PAGE using Coomassie brilliant blue staining.
Statistics
Antibody titers and RBL-assay results were statistically
compared using the non-parametric Mann-Whitney U test with
the SPSS 18.0 program. A P value ,0.05 was considered
statistically significant.
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